Jure-Kunkel; Maria

Patent Applications and Registrations

Patent applications and USPTO patent grants for Jure-Kunkel; Maria.The latest application filed is for "cancer immunotherapy by disrupting pd-1/pd-l1 signaling".

Company Profile

26.32.47

Jure-Kunkel; Maria - Plainsboro NJ
JURE-KUNKEL; Maria - Princeton NJ

*profile and listings may contain filings by different individuals or companies with the same name. Review application materials to confirm ownership/assignment.

Patent Activity

Patent	Date
PET imaging with PD-L1 binding polypeptides Grant 11,344,639 - Morin , et al. May 31, 2	2022-05-31
PD-L1 binding polypeptides for imaging Grant 11,173,219 - Morin , et al. November 16, 2	2021-11-16
Cancer Immunotherapy By Disrupting Pd-1/pd-l1 Signaling App 20200308282 - COGSWELL; John P. ; et al.	2020-10-01
Cancer immunotherapy by disrupting PD-1/PD-L1 signaling Grant 10,604,575 - Cogswell , et al.	2020-03-31
Cancer immunotherapy by disrupting PD-1/PD-L1 signaling Grant 10,584,170 - Cogswell , et al.	2020-03-10
Cancer immunotherapy by disrupting PD-1/PD-L1 signaling Grant 10,577,423 - Cogswell , et al.	2020-03-03
Treatment Of Cancer Using A Combination Of An Anti-pd-1 Antibody And Anti-cd137 App 20190382491 - Jure-Kunkel; Maria ; et al.	2019-12-19
Combination Therapy With Anti-cd73 Antibodies App 20190284293 - LONBERG; Nils ; et al.	2019-09-19
Treatment Of Renal Cancer Using A Combination Of An Anti-pd-1 Antibody And Another Anti-cancer Agent App 20190263923 - JURE-KUNKEL; Maria ; et al.	2019-08-29
Pet Imaging With Pd-l1 Binding Polypeptides App 20190184042 - MORIN; Paul E. ; et al.	2019-06-20
Cancer immunotherapy by disrupting PD-1/PD-L1 signaling Grant 10,323,093 - Cogswell , et al.	2019-06-18
Cancer immunotherapy by disrupting PD-1/PD-L1 signaling Grant 10,323,092 - Cogswell , et al.	2019-06-18
Cancer immunotherapy by disrupting PD-1/PD-L1 signaling Grant 10,316,090 - Cogswell , et al.	2019-06-11
Cancer immunotherapy by disrupting PD-1/PD-L1 signaling Grant 10,316,091 - Cogswell , et al.	2019-06-11
Cancer immunotherapy by disrupting PD-1/PD-L1 signaling Grant 10,308,714 - Cogswell , et al.	2019-06-04
Cancer Immunotherapy By Disrupting Pd-1/pd-l1 Signaling App 20190153099 - COGSWELL; John P. ; et al.	2019-05-23
Cancer Immunotherapy By Disrupting Pd-1/pd-l1 Signaling App 20190135920 - Cogswell; John P. ; et al.	2019-05-09
Cancer immunotherapy by disrupting PD-1/PD-L1 signaling Grant 10,266,594 - Cogswell , et al.	2019-04-23
Cancer immunotherapy by disrupting PD-1/PD-L1 signaling Grant 10,266,596 - Cogswell , et al.	2019-04-23
Cancer immunotherapy by disrupting PD-1/PD-L1 signaling Grant 10,266,595 - Cogswell , et al.	2019-04-23
Cancer Immunotherapy By Disrupting Pd-1/pd-l1 Signaling App 20190112376 - COGSWELL; John P. ; et al.	2019-04-18
Cancer Immunotherapy By Disrupting Pd-1/pd-l1 Signaling App 20190112377 - COGSWELL; John P. ; et al.	2019-04-18
Cancer Immunotherapy By Disrupting Pd-1/pd-l1 Signaling App 20190100589 - Cogswell; John P. ; et al.	2019-04-04
Cancer Immunotherapy By Disrupting Pd-1/pd-l1 Signaling App 20190100590 - Cogswell; John P. ; et al.	2019-04-04
Cancer Immunotherapy By Disrupting Pd-1/pd-l1 Signaling App 20190092863 - Cogswell; John P. ; et al.	2019-03-28
Fully Human Antibodies Against Human 4-1bb App 20190062445 - Jure-Kunkel; Maria ; et al.	2019-02-28
Antibodies Against Cd73 And Uses Thereof App 20190062456 - Lonberg; Nils ; et al.	2019-02-28
Antibodies Against Cd73 And Uses Thereof App 20190055320 - LONBERG; Nils ; et al.	2019-02-21
Cancer immunotherapy by disrupting PD-1/PD-L1 signaling Grant 10,138,299 - Cogswell , et al. Nov	2018-11-27
Cancer Immunotherapy By Disrupting Pd-1/pd-l1 Signaling App 20180319887 - Cogswell; John P. ; et al.	2018-11-08
Cancer Immunotherapy By Disrupting Pd-1/pd-l1 Signaling App 20180312590 - COGSWELL; John P. ; et al.	2018-11-01
Antibodies against CD73 and uses thereof Grant 10,100,129 - Lonberg , et al. October 16, 2	2018-10-16
Cancer Immunotherapy By Disrupting Pd-1/pd-l1 Signaling App 20180282414 - COGSWELL; John P. ; et al.	2018-10-04
Cancer Immunotherapy By Disrupting Pd-1/pd-l1 Signaling App 20180282413 - COGSWELL; John P. ; et al.	2018-10-04
Cancer Immunotherapy By Disrupting Pd-1/pd-l1 Signaling App 20180273624 - COGSWELL; John P. ; et al.	2018-09-27
Cancer immunotherapy by disrupting PD-1/PD-L1 signaling Grant 10,072,082 - Cogswell , et al. September 11, 2	2018-09-11
Antibodies Against Ox40 And Uses Thereof App 20180237534 - CAI; Zhehong ; et al.	2018-08-23
Antibodies Against Cd73 And Uses Thereof App 20180127513 - LONBERG; Nils ; et al.	2018-05-10
Cancer immunotherapy by disrupting PD-1/PD-L1 signaling Grant 9,856,320 - Cogswell , et al. January 2, 2	2018-01-02
Treatment Of Cancer Using A Combination Of An Anti-pd-1 Antibody And An Anti-cd137 Antibody App 20170247455 - JURE-KUNKEL; Maria ; et al.	2017-08-31
Treatment Of Renal Cancer Using A Combination Of An Anti-pd-1 Antibody And Another Anti-cancer Agent App 20170088626 - JURE-KUNKEL; Maria ; et al.	2017-03-30
Fully Human Antibodies Against Human 4-1bb App 20160368998 - JURE-KUNKEL; Maria ; et al.	2016-12-22
Antibodies Against Ox40 And Uses Thereof App 20160347849 - CAI; Zhehong ; et al.	2016-12-01
Immunotherapeutic Dosing Regimens And Combinations Thereof App 20160264670 - Graziano; Robert F ; et al.	2016-09-15
Fully human antibodies against human 4-1BB Grant 9,382,328 - Jure-Kunkel , et al. July 5, 2	2016-07-05
Combination of anti-CTLA4 antibody with diverse therapeutic regimens for the synergistic treatment of proliferative diseases Grant 9,320,811 - Jure-Kunkel April 26, 2	2016-04-26
Cancer Immunotherapy By Disrupting Pd-1/pd-l1 Signaling App 20160090417 - COGSWELL; JOHN P. ; et al.	2016-03-31
Antibodies that bind PD-L1 and uses thereof Grant 9,212,224 - Cogswell , et al. December 15, 2	2015-12-15
Cancer Immunotherapy By Disrupting Pd-1/pd-l1 Signaling App 20150125463 - Cogswell; John P. ; et al.	2015-05-07
Combination Of Anti-ctla4 Antibody With Tubulin Modulating Agents For The Treatment Of Proliferative Diseases App 20140323533 - Jure-Kunkel; Maria	2014-10-30
Fully Human Antibodies Against Human 4-1bb App 20140193422 - Jure-Kunkel; Maria ; et al.	2014-07-10
Combination Of Anti-ctla4 Antibody With Diverse Therapeutic Regimens For The Synergistic Treatment Of Proliferative Diseases App 20140141024 - Jure-Kunkel; Maria ; et al.	2014-05-22
Fully human antibodies against human 4-1BB Grant 8,716,452 - Jure-Kunkel , et al. May 6, 2	2014-05-06
Combination of anti-CTLA4 antibody with diverse therapeutic regimens for the synergistic treatment of proliferative diseases Grant 8,685,394 - Jure-Kunkel April 1, 2	2014-04-01
Cancer Immunotherapy By Disrupting Pd-1/pd-l1 Signaling App 20130309250 - Cogswell; John ; et al.	2013-11-21
Combination of CD137 antibody and CTLA-4 antibody for the treatment of proliferative diseases Grant 8,475,790 - Jure-Kunkel July 2, 2	2013-07-02
Combination Of Anti-ctla4 Antibody With Braf Inhibitors For The Synergistic Treatment Of Proliferative Diseases App 20130156768 - Jure-Kunkel; Maria ; et al.	2013-06-20
Combination Of Anti-ctla4 Antibody With Diverse Therapeutic Regimens For The Synergistic Treatment Of Proliferative Diseases App 20130142805 - Jure-Kunkel; Maria ; et al.	2013-06-06
Combination of anti-CTLA4 antibody with tubulin modulating agents for the treatment of proliferative diseases Grant 8,449,886 - Jure-Kunkel May 28, 2	2013-05-28
Fully Human Antibodies Against Human 4-1bb App 20120141494 - Jure-Kunkel; Maria ; et al.	2012-06-07
Combination Of Anti-ctla4 Antibody With Dasatinib For The Treatment Of Proliferative Diseases App 20120135001 - Jure-Kunkel; Maria ; et al.	2012-05-31
Combination Of Anti-ctla4 Antibody With Diverse Therapeutic Regimens For The Synergistic Treatment Of Proliferative Diseases App 20120121604 - Jure-Kunkel; Maria ; et al.	2012-05-17
Fully human antibodies against human 4-1BB Grant 8,137,667 - Jure-Kunkel , et al. March 20, 2	2012-03-20
Combination of anti-CTLA4 antibody with dasatinib for the treatment of proliferative diseases Grant 8,119,129 - Jure-Kunkel , et al. February 21, 2	2012-02-21
Combination Of Cd137 Antibody And Ctla-4 Antibody For The Treatment Of Proliferative Diseases App 20110189189 - Jure-Kunkel; Maria	2011-08-04
Combination Of Anti-ctla4 Antibody With Tubulin Modulating Agents For The Treatment Of Proliferative Diseases App 20100278828 - Jure-Kunkel; Maria	2010-11-04
Fully human antibodies against human 4-1BB App 20100183621 - Jure-Kunkel; Maria ; et al.	2010-07-22
Combination of anti-CTLA4 antibody with dasatinib for the treatment of proliferative diseases App 20100098701 - Jure-Kunkel; Maria ; et al.	2010-04-22
Biomarkers And Methods For Determining Sensitivity To Ctla-4 Antagonists App 20100099090 - Tsuchihashi; Zenta ; et al.	2010-04-22
Polynucleotides encoding fully human antibodies against human 4-1BB Grant 7,659,384 - Jure-Kunkel , et al. February 9, 2	2010-02-09
Fully human antibodies against human 4-1BB App 20090068192 - Jure-Kunkel; Maria ; et al.	2009-03-12
Fully human antibodies against human 4-1BB Grant 7,288,638 - Jure-Kunkel , et al. October 30, 2	2007-10-30
Fully human antibodies against human 4-1BB App 20050095244 - Jure-Kunkel, Maria ; et al.	2005-05-05

uspto.report is an independent third-party trademark research tool that is not affiliated, endorsed, or sponsored by the United States Patent and Trademark Office (USPTO) or any other governmental organization. The information provided by uspto.report is based on publicly available data at the time of writing and is intended for informational purposes only.

While we strive to provide accurate and up-to-date information, we do not guarantee the accuracy, completeness, reliability, or suitability of the information displayed on this site. The use of this site is at your own risk. Any reliance you place on such information is therefore strictly at your own risk.

All official trademark data, including owner information, should be verified by visiting the official USPTO website at www.uspto.gov. This site is not intended to replace professional legal advice and should not be used as a substitute for consulting with a legal professional who is knowledgeable about trademark law.